PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS

PREVNAR C295 ISS 婴儿狒狒疫苗配方

• 批准号: 7562449
• 负责人: KATHLEEN M BRASKY
• 金额: $ 0.13万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562449
• 关键词: Adult; Antibody Formation; Antigens; Computer Retrieval of Information on Scientific Projects Database; DNA Sequence; Development; Drug Formulations; Funding; Grant; Human; Infant; Institution; Papio; Pneumococcal vaccine; Polysaccharides; Prevnar; Research; Research Personnel; Resources; Source; Testing; Time; United States National Institutes of Health; Vaccines; immunogenicity; improved; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to test for the first time in infant baboons the immunogenicity of a commercial pneumococcal 7-valent vaccine formulation (PREVNAR¿) alone, or in combination immunostimulatory DNA sequences (C295 ISS and C295-PMXB). PREVNAR¿ vaccine in combination with C295 ISS or C295-PMXB was tested in adult baboons (952-PC-0) and was shown to be safe. This study will help decide if PREVNAR¿ combined with C295 ISS or C295-PMXB vaccine formulation can elicit improved antibody responses in infant baboons to pneumococcal polysaccharide antigens, which will assist in the development of a new pneumococcal vaccine for human infants.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本实验的目的是首次在婴儿狒狒中测试商业肺炎球菌 7 价疫苗制剂 (PREVNAR¿) 单独或组合免疫刺激 DNA 序列（C295 ISS 和 C295-PMXB）的免疫原性。 PREVNAR¿ 疫苗与 C295 ISS 或 C295-PMXB 组合在成年狒狒 (952-PC-0) 中进行了测试，结果显示是安全的。 这项研究将有助于确定 PREVNAR¿ 与 C295 ISS 或 C295-PMXB 疫苗配方相结合是否可以改善婴儿狒狒对肺炎球菌多糖抗原的抗体反应，这将有助于为人类婴儿开发新型肺炎球菌疫苗。